Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Oncol. 2003 Apr 15;21(8):1637-47. Epub 2003 Mar 13.

Practical management of patients with chronic myeloid leukemia receiving imatinib.

Author information

1
Oregon Health and Science University Cancer Institute, L592, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA. drukerb@ohsu.edu

Abstract

The introduction of imatinib, a specific inhibitor of the Bcr-Abl tyrosine kinase, has dramatically changed the management of chronic myeloid leukemia (CML). More than 10,000 patients worldwide have been treated with imatinib in clinical trials, and a large body of information has accumulated about the use of this drug. The purpose of this article is to review practical guidelines in regard to optimal dosing, monitoring, managing common side effects such as myelosuppression, and potential drug interactions. The treatment recommendations are intended to optimize therapy with imatinib while taking into account a patient's specific circumstances.

PMID:
12668652
DOI:
10.1200/JCO.2003.11.143
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center